Cytokinetics, Incorporated (CYTK): Price and Financial Metrics

Cytokinetics, Incorporated (CYTK)

Today's Latest Price: $19.89 USD

0.93 (4.91%)

Updated Jan 19 4:00pm

Add CYTK to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 483 in Biotech

See all "A" rated Strong Buy stocks

CYTK Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at 84.22 for Cytokinetics Inc; that's greater than it is for 99.71% of US stocks.
  • With a year-over-year growth in debt of 167.1%, Cytokinetics Inc's debt growth rate surpasses 92.01% of about US stocks.
  • As for revenue growth, note that CYTK's revenue has grown 75.03% over the past 12 months; that beats the revenue growth of 92.93% of US companies in our set.
  • Stocks that are quantitatively similar to CYTK, based on their financial statements, market capitalization, and price volatility, are QTNT, MCRB, PHUN, EVRI, and HNGR.
  • Visit CYTK's SEC page to see the company's official filings. To visit the company's web site, go to

CYTK Stock Price Chart Interactive Chart >

Price chart for CYTK

CYTK Price/Volume Stats

Current price $19.89 52-week high $30.14
Prev. close $18.96 52-week low $8.00
Day low $18.91 Volume 851,000
Day high $19.97 Avg. volume 929,873
50-day MA $18.74 Dividend yield N/A
200-day MA $20.23 Market Cap 1.41B

Cytokinetics, Incorporated (CYTK) Company Bio

Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The company was founded in 1997 and is based in South San Francisco, California.

CYTK Latest News Stream

Event/Time News Detail
Loading, please wait...

CYTK Latest Social Stream

Loading social stream, please wait...

View Full CYTK Social Stream

Latest CYTK News From Around the Web

Below are the latest news stories about Cytokinetics Inc that investors may wish to consider to help them evaluate CYTK as an investment opportunity.

Cytokinetics Announces First Patient Dosed in Cohort 2 of Redwood-HCM

Company Earns $2.5 Million Milestone Payment from Ji Xing PharmaceuticalsSOUTH SAN FRANCISCO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced that the first patient has been dosed in Cohort 2 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase 2 clinical trial of CK-3773274 (CK-274), a next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM). This event triggers a $2.5 million milestone payment payable from Ji Xing Pharmaceuticals Limited to Cytokinetics under the License and Collaboration Agreement between the companies. REDWOOD-HCM: Clinical Trial DesignREDWOOD-HCM is a multi-center, randomized, placebo-controlled...

Yahoo | January 13, 2021

Cytokinetics' CK-274 an orphan drug in U.S. for hypertrophic cardiomyopathy

The FDA has granted orphan drug designation to Cytokinetics' (CYTK) CK-3773274 (CK-274) for the treatment of symptomatic hypertrophic cardiomyopathy ((HCM)).Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved. HCM is a disease in which the heart muscle...

Seeking Alpha | January 11, 2021

Cytokinetics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President…

GlobeNewswire | January 6, 2021

Cytokinetics Regains European Rights to Omecamtiv Mecarbil

Company is Planning Regulatory Interactions in 2021 to Discuss Results of GALACTIC-HF and Expects to Evaluate Strategic Options for Co-Commercialization and LicensingSOUTH SAN FRANCISCO, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that Amgen Inc. (“Amgen”) notified the company that Les Laboratoires Servier and Institut de Recherches Internationales Servier (“Servier”) elected to terminate the sublicense agreement between Amgen and Servier (the “Servier Agreement”) for the development and commercialization of omecamtiv mecarbil in Europe and the Commonwealth of Independent States, including Russia. The termination is effective as of March 18, 2021, after which all development, commercialization and other rights with respect to omecamtiv m...

Yahoo | December 23, 2020

10 Best Biotech Stocks to Invest In According To Billionaire Biotech Hedge Fund

In this article, we will present the 10 best stocks to invest in according to the billionaire biotech hedge fund manager Joe Edelman. Click to skip ahead and see the 5 Best Biotech Stocks to Invest In. Joseph Edelman is one of the most successful biotech hedge fund portfolio managers since he founded Perceptive Advisors […]

Yahoo | December 19, 2020

Read More 'CYTK' Stories Here

CYTK Price Returns

1-mo -6.27%
3-mo 26.69%
6-mo -17.91%
1-year N/A
3-year 107.19%
5-year 146.77%
YTD -4.28%
2020 95.85%
2019 67.88%
2018 -22.45%
2017 -32.92%
2016 16.16%

Continue Researching CYTK

Want to see what other sources are saying about Cytokinetics Inc's financials and stock price? Try the links below:

Cytokinetics Inc (CYTK) Stock Price | Nasdaq
Cytokinetics Inc (CYTK) Stock Quote, History and News - Yahoo Finance
Cytokinetics Inc (CYTK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7725 seconds.